Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    0.00 (0.00%)
Bid:
143.00
Ask:
145.00
Spread: 2.00 (1.399%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Board changes

30 May 2024 12:00

RNS Number : 4436Q
Xaar PLC
30 May 2024
 

30 May 2024

 

Xaar plc

 

Board changes

 

Xaar plc ("Xaar" or "the Group" or "the Company"), the leading inkjet printing technology group, is pleased to announce the appointment of Dr Inken Braunschmidt as Independent Non-Executive Director.

 

Inken joins the Board with effect from 1 June 2024 and on appointment will be a member of the Audit, Remuneration and Nomination Committees.

 

As previously disclosed, Alison Littley had notified the Board of her intention to step down as a Non-Executive Director of the Company during 2024. It is now confirmed that Alison will leave the Board on 30 June 2024. Inken will be appointed as Chair of Remuneration Committee on 1 July 2024.

 

Richard Amos, Non-Executive Director, will replace Alison Littley as the Company's Senior Independent Director on 1 July 2024.

 

Inken Braunschmidt is currently a non-executive director of James Fisher and Sons plc, listed on the London Stock Exchange, and Chair of its Remuneration Committee as well as a member of the Audit and Nomination Committees. She was Chief Innovation and Digital Officer and member of the Executive Board of Halma plc until 2023. Prior to joining Halma plc in 2017, Inken spent 13 years at RWE AG, the German energy giant, and its renewables subsidiary innogy SE, where she held various international leadership roles focusing on strategy, innovation, digital transformation and change management. Inken studied Business Administration, Innovation & Technology Management at Kiel University and did her PhD thesis in Technology Management. Inken is member of the Digital Programme Board of the Royal Academy of Engineering.

 

 

Andrew Herbert, Chairman, commented:

 

"We are delighted to welcome Inken to the Board and her expertise and experience in international electronic engineering and digital innovation and transformation are very relevant to the opportunities and challenges that face Xaar. I would like to thank Alison for her contribution and commitment to the Board of Xaar as a director since 2020 and wish her the very best for the future."

 

The Company confirms there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to the appointment of Inken Braunschmidt.

 

Enquiries:

 

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

John Mills, Chief Executive Officer

 

Teneo

Giles Kernick

Olivia Lucas

+44 (0) 207 353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAURAWRSAUVORR
Date   Source Headline
1st Jul 20221:10 pmRNSTotal Voting Rights
21st Jun 20225:20 pmRNSDirector Declaration - Additional Directorship
1st Jun 202210:22 amRNSTotal Voting Rights
25th May 20221:57 pmRNSResult of AGM
3rd May 20225:20 pmRNSTotal Voting Rights
7th Apr 20226:31 pmRNSPDMR Shareholding
7th Apr 20222:50 pmRNSGrant of Options and Deferred Bonus Share Awards
1st Apr 202210:48 amRNSTotal Voting Rights
29th Mar 20227:00 amRNS2021 Full Year Results
28th Mar 202210:44 amRNSHolding(s) in Company
21st Mar 202212:37 pmRNSNotice of 2021 Preliminary Results
3rd Mar 20227:00 amRNSAcquisition of Megnajet
1st Mar 20225:29 pmRNSTotal Voting Rights
1st Feb 20225:00 pmRNSTotal Voting Rights
18th Jan 20224:35 pmRNSPrice Monitoring Extension
13th Jan 20227:00 amRNSTrading Update
4th Jan 20222:39 pmRNSBlock listing Interim Review
4th Jan 20222:37 pmRNSTotal Voting Rights
10th Dec 20214:23 pmRNSGrant of Awards - Replacement
6th Dec 202112:25 pmRNSHolding(s) in Company
1st Dec 20215:00 pmRNSTotal Voting Rights
5th Nov 202110:30 amRNSGrant of Sharesave Options
1st Nov 20214:11 pmRNSCompletion of Divestment of Xaar 3D
1st Nov 20211:56 pmRNSTotal Voting Rights
29th Oct 20214:41 pmRNSSecond Price Monitoring Extn
29th Oct 20214:36 pmRNSPrice Monitoring Extension
25th Oct 202110:38 amRNSResult of General Meeting
15th Oct 202111:50 amRNSGrant of Options and Deferred Bonus Share Awards
14th Oct 20218:44 amRNSBlock Listing Application
13th Oct 20212:52 pmRNSHolding(s) in Company
6th Oct 20212:43 pmRNSPublication of Circular and Notice of GM
6th Oct 20217:00 amRNSProposed divestment of Xaar 3D
1st Oct 202111:59 amRNSTotal Voting Rights
14th Sep 20217:00 amRNS2021 Interim Results
3rd Sep 202112:59 pmRNSNotice of 2021 Interim Results
2nd Sep 20213:40 pmRNSTotal Voting Rights
2nd Aug 20215:02 pmRNSTotal Voting Rights
22nd Jul 20217:00 amRNSTrading Update
12th Jul 20217:00 amRNSAcquisition of FFEI
1st Jul 20213:20 pmRNSBlock listing Interim Review
1st Jul 202110:51 amRNSTotal Voting Rights
22nd Jun 20215:37 pmRNSHolding(s) in Company
22nd Jun 202111:44 amRNSHolding(s) in Company
16th Jun 20211:17 pmRNSResult of AGM
1st Jun 202110:10 amRNSTotal Voting Rights
17th May 20219:27 amRNSHolding(s) in Company
12th May 202110:15 amRNSHolding(s) in Company
4th May 20213:01 pmRNSTotal Voting Rights
30th Apr 20216:23 pmRNSAnnual Financial Report
27th Apr 20217:00 amRNS2020 FULL YEAR RESULTS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.